Cancer Research (journal)

January 16, 2024

Data haul improves immunotherapy response prediction

Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.

By Paul Govern
January 14, 2022

Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

By Tom Wilemon
June 4, 2020

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

By Bill Snyder
September 19, 2019

Potential prostate cancer biomarkers

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.

By Leigh MacMillan
December 13, 2018

Breast cancer-killing RIG

A compound that activates a virus-sensing receptor has potent therapeutic effects in a mouse model of breast cancer.

By Leigh MacMillan
April 20, 2017

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

By VUMC News and Communications
September 9, 2016

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.
By Leigh MacMillan
August 26, 2016

New breast cancer driver

Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers.
By Leigh MacMillan
April 14, 2016

Switching breast cancer off

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.
By Marilyn Holt
February 10, 2016

Overcoming lung cancer drug resistance

Vanderbilt investigators have discovered a way to overcome the resistance of some lung cancers to certain targeted therapies, which could lead to more effective treatments for lung cancer patients.
By Marilyn Holt
February 9, 2015

Gene profile predicts metastasis

A specific gene expression profile represents a novel, biologically relevant “signature” for identifying colon cancers with high risk of metastatic recurrence, Vanderbilt researchers have found.
By Yan Su
January 8, 2015

Study tracks combination therapy to treat melanoma

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances.
By VUMC News and Communications
November 6, 2014

Immune cell activity and melanoma

The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.
By VUMC News and Communications
1 2